Ig Vena

Human Normal Immunoglobulin, the active ingredient in Ig Vena, is an immunoglobulin presented as a solution for injection for intravenous use. It provides passive immunity and is used to replace deficient antibodies in patients with primary or secondary immunodeficiency, as well as certain immune‑mediated disorders such as ITP, Kawasaki disease, CIDP and multifocal motor neuropathy.

GNH USA supplies Ig Vena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ig Vena, an intravenous immunoglobulin, is used to replace deficient antibodies and modulate immune activity in several immunologic conditions.

- Primary immunodeficiency diseases: restores normal IgG levels to reduce infection frequency. - Secondary immunodeficiency (e.g., chemotherapy‑induced): provides passive immunity during immune suppression. - Idiopathic thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity. - Kawasaki disease: reduces coronary artery inflammation in the acute phase. - Chronic inflammatory demyelinating polyneuropathy (CIDP): improves muscle strength and functional ability. - Multifocal motor neuropathy: alleviates motor weakness through immune modulation.

Ig Vena may be associated with a range of infusion‑related and immunologic reactions.

Common Side Effects: - Headache: mild to moderate, often transient. - Fever or chills: typical during or shortly after infusion. - Fatigue: generalized tiredness reported by some patients. - Nausea: occasional gastrointestinal upset. - Arthralgia: joint discomfort during treatment. - Myalgia: muscle aches following infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: clot formation in veins or arteries. - Acute renal failure: especially in patients with pre‑existing kidney disease. - Aseptic meningitis: inflammation of meninges without infection. - Hemolysis: destruction of red blood cells. - Severe thrombocytopenia: marked drop in platelet count.

Before initiating Ig Vena therapy, several safety considerations should be observed.

- Screen for IgA deficiency: assess risk of anti‑IgA antibodies before infusion. - Monitor vital signs: observe for infusion reactions during and after administration. - Adjust infusion rate: start slow and increase as tolerated to reduce adverse events. - Avoid concurrent live vaccines: immunoglobulin may neutralize vaccine efficacy. - Renal function: use caution in patients with pre‑existing kidney disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Live attenuated vaccines: immunoglobulin may neutralize vaccine organisms. - Cytotoxic chemotherapy: combined use may heighten risk of renal toxicity. - High‑dose corticosteroids: may amplify overall immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): IgV may affect INR and bleeding risk. - ACE inhibitors: rare reports of angioedema when used together. - Non‑live vaccines: possible alteration of immune response, requiring monitoring of antibody titres.